HSCSW 10-Q Filings - HeartSciences Inc. Warrant SEC 10-Q
HeartSciences Inc. (HSCS) reported a net loss of $3.17M for Q2 2026, wider than the prior-year loss, with revenue at $2,100. Cash fell to $29,906, and stockholders' equity deficit reached $2.03M, prompting a Nasdaq compliance notice. Management expressed doubt about the company's going concern status and is pursuing a merger and capital raises.
How this was made
The 30-second read
Why it matters
The 10‑Q reveals ongoing cash burn, a Nasdaq equity deficiency, and reliance on a private placement, indicating short‑term downside risk.
Market read
The filing underscores liquidity concerns and a potential delisting, which are material for traders holding or shorting HSCSW.
What to watch
Potential upside from the upcoming FDA submission for MyoVista wav ECG.
Background
HeartSciences (HSCSW) is a micro‑cap biotech that recently completed a 100‑for‑1 reverse split and is pursuing a merger with Fortitude Mining HoldCo.
Ticker impact
HeartSciences filed its latest 10‑Q showing a $2,100 revenue quarter, a $3.17 M net loss and a Nasdaq listing deficiency.
downward pressure until compliance is restored or new capital is raised
Listing deficiency and ongoing going‑concern doubts are material for investors in a micro‑cap.
Market effects
Highlights risks for other small‑cap biotech firms facing cash constraints.
Limited to U.S. OTC market participants.
Minimal beyond niche biotech investors.
Counterpoint
If the merger with Fortitude succeeds, the combined entity could regain compliance and spark a rebound.
Key entities
- companyHeartSciences Inc.
Micro‑cap biotech filing its quarterly report.
- companyFortitude Mining HoldCo
Proposed merger partner expected to own ~95% of the combined entity.
